The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited
The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
Cidara will become a wholly owned subsidiary of Merck and the common stock of Cidara will no longer be listed or traded on the Nasdaq Global Market
It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,
CuraTeQ Biologics and BioFactura USA to terminate agreement mutually
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products
The move strengthens Sanofi’s presence in adult immunization by combining Dynavax’s innovative vaccines with Sanofi’s global scale and development capabilities
Subscribe To Our Newsletter & Stay Updated
